메뉴 건너뛰기




Volumn 46, Issue 4, 2005, Pages 637-642

Calcium antagonists: Effects on cardio-renal risk in hypertensive patients

Author keywords

Calcium antagonists; Cardiovascular risk; Hypertension; Renal disease

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHLORTALIDONE; CLONIDINE; DOXAZOSIN; LISINOPRIL; RESERPINE; TRANDOLAPRIL; VERAPAMIL;

EID: 30544437878     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000184541.24700.c7     Document Type: Review
Times cited : (72)

References (66)
  • 2
    • 0037527647 scopus 로고    scopus 로고
    • 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension
    • 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-1053.
    • (2003) J Hypertens , vol.21 , pp. 1011-1053
  • 3
    • 0242654867 scopus 로고    scopus 로고
    • Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials
    • Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527-1535.
    • (2003) Lancet , vol.362 , pp. 1527-1535
    • Turnbull, F.1
  • 4
    • 0038203004 scopus 로고    scopus 로고
    • Cardiovascular prevention and blood pressure reduction: A quantitative overview updated until 1 March 2003
    • Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens. 2003;21:1055-1076.
    • (2003) J Hypertens , vol.21 , pp. 1055-1076
    • Staessen, J.A.1    Wang, J.G.2    Thijs, L.3
  • 5
    • 22144477948 scopus 로고    scopus 로고
    • Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: Results of prospectively designed overviews of randomized trials
    • Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165:1410-1419.
    • (2005) Arch Intern Med , vol.165 , pp. 1410-1419
  • 7
    • 4043124049 scopus 로고    scopus 로고
    • Cardiovascular therapies and risk for development of diabetes
    • Pepine CJ, Cooper-Dehoff RM. Cardiovascular therapies and risk for development of diabetes. J Am Coll Cardiol. 2004;44:509-512.
    • (2004) J Am Coll Cardiol , vol.44 , pp. 509-512
    • Pepine, C.J.1    Cooper-Dehoff, R.M.2
  • 10
    • 0029132121 scopus 로고
    • Nifedipine. Dose-related increase in mortality in patients with coronary heart disease
    • Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995;92:1326-1331.
    • (1995) Circulation , vol.92 , pp. 1326-1331
    • Furberg, C.D.1    Psaty, B.M.2    Meyer, J.V.3
  • 11
    • 0028860846 scopus 로고
    • Should calcium antagonists be first line drugs in hypertension?
    • Furberg CD, Psaty BM. Should calcium antagonists be first line drugs in hypertension? Herz. 1995;20:365-369.
    • (1995) Herz , vol.20 , pp. 365-369
    • Furberg, C.D.1    Psaty, B.M.2
  • 12
    • 0030021828 scopus 로고    scopus 로고
    • FDA gives calcium channel blockers clean bill of health but warns of short-acting nifedipine hazards
    • Marwick C. FDA gives calcium channel blockers clean bill of health but warns of short-acting nifedipine hazards. JAMA. 1996;275:423-424.
    • (1996) JAMA , vol.275 , pp. 423-424
    • Marwick, C.1
  • 13
    • 0034627164 scopus 로고    scopus 로고
    • Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: A meta-analysis of randomised controlled trials
    • Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Cavazzini C, Furberg CD. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet. 2000;356:1949-1954.
    • (2000) Lancet , vol.356 , pp. 1949-1954
    • Pahor, M.1    Psaty, B.M.2    Alderman, M.H.3    Applegate, W.B.4    Williamson, J.D.5    Cavazzini, C.6    Furberg, C.D.7
  • 17
    • 2642642140 scopus 로고    scopus 로고
    • Comparative pharmacological properties among calcium channel blockers: T-channel versus L-channel blockade
    • Noll G, Luscher TF. Comparative pharmacological properties among calcium channel blockers: T-channel versus L-channel blockade. Cardiology. 1998;(89 Suppl 1):10-15.
    • (1998) Cardiology , Issue.89 SUPPL. 1 , pp. 10-15
    • Noll, G.1    Luscher, T.F.2
  • 19
    • 0027089915 scopus 로고
    • Selectivity scale of calcium antagonists in the human cardiovascular system based on in vitro studies
    • Godfraind T, Salomone S, Dessy C, Verhelst B, Dion R, Schoevaerts JC. Selectivity scale of calcium antagonists in the human cardiovascular system based on in vitro studies. J Cardiovasc Pharmacol. 1992;20(Suppl 5):S34-S41.
    • (1992) J Cardiovasc Pharmacol , vol.20 , Issue.5 SUPPL.
    • Godfraind, T.1    Salomone, S.2    Dessy, C.3    Verhelst, B.4    Dion, R.5    Schoevaerts, J.C.6
  • 20
    • 0030049628 scopus 로고    scopus 로고
    • Opie ••. luteinizing hormone (LH). Calcium channel antagonists in the treatment of coronary artery disease: Fundamental pharmacological properties relevant to clinical use
    • Opie ••. luteinizing hormone (LH). Calcium channel antagonists in the treatment of coronary artery disease: fundamental pharmacological properties relevant to clinical use. Prog Cardiovasc Dis. 1996;38:273-290.
    • (1996) Prog Cardiovasc Dis , vol.38 , pp. 273-290
  • 22
    • 0034106766 scopus 로고    scopus 로고
    • Felodipine improves left ventricular emptying in patients with chronic heart failure: V-HeFT III echocardiographic substudy of multicenter reproducibility and detecting functional change
    • Wong M, Germanson T, Taylor WR, Cohen IS, Perry G, Baruch L, Deedwania P, Lopez B, Cohn JN. Felodipine improves left ventricular emptying in patients with chronic heart failure: V-HeFT III echocardiographic substudy of multicenter reproducibility and detecting functional change. J Card Fail. 2000;6:19-28.
    • (2000) J Card Fail , vol.6 , pp. 19-28
    • Wong, M.1    Germanson, T.2    Taylor, W.R.3    Cohen, I.S.4    Perry, G.5    Baruch, L.6    Deedwania, P.7    Lopez, B.8    Cohn, J.N.9
  • 23
    • 0033973435 scopus 로고    scopus 로고
    • Efficacy and safety of calcium channel blockers in heart failure: Focus on recent trials with second-generation dihydropyridines
    • de Vries RJ, van Veldhuisen DJ, Dunselman PH. Efficacy and safety of calcium channel blockers in heart failure: focus on recent trials with second-generation dihydropyridines. Am Heart J. 2000;139(2 Pt 1):185-194.
    • (2000) Am Heart J , vol.139 , Issue.2 PART 1 , pp. 185-194
    • De Vries, R.J.1    Van Veldhuisen, D.J.2    Dunselman, P.H.3
  • 25
    • 0035818884 scopus 로고    scopus 로고
    • A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure
    • Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675.
    • (2001) N Engl J Med , vol.345 , pp. 1667-1675
    • Cohn, J.N.1    Tognoni, G.2
  • 26
    • 0344373794 scopus 로고    scopus 로고
    • Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    • Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
    • (2002) JAMA , vol.288 , pp. 2981-2997
  • 31
    • 23744493793 scopus 로고    scopus 로고
    • Clinical trials update from the European Society of Cardiology Heart Failure meeting and the American College of Cardiology: Darbepoetin alfa study, ECHOS, and ASCOT-BPLA
    • Cleland JG, Coletta AP, Clark AL, Velavan P, Ingle L. Clinical trials update from the European Society of Cardiology Heart Failure meeting and the American College of Cardiology: Darbepoetin alfa study, ECHOS, and ASCOT-BPLA. Eur J Heart Fail. 2005;7:937-939.
    • (2005) Eur J Heart Fail , vol.7 , pp. 937-939
    • Cleland, J.G.1    Coletta, A.P.2    Clark, A.L.3    Velavan, P.4    Ingle, L.5
  • 32
    • 0034730027 scopus 로고    scopus 로고
    • Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study
    • Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, Lanke J, de Faire U, Dahlof B, Karlberg BE. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet. 2000;356:359-365.
    • (2000) Lancet , vol.356 , pp. 359-365
    • Hansson, L.1    Hedner, T.2    Lund-Johansen, P.3    Kjeldsen, S.E.4    Lindholm, L.H.5    Syvertsen, J.O.6    Lanke, J.7    De Faire, U.8    Dahlof, B.9    Karlberg, B.E.10
  • 33
    • 0029845252 scopus 로고    scopus 로고
    • Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy
    • Epstein M, Bakris G. Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy. Arch Intern Med. 1996;156:1969-1978.
    • (1996) Arch Intern Med , vol.156 , pp. 1969-1978
    • Epstein, M.1    Bakris, G.2
  • 34
    • 0034074955 scopus 로고    scopus 로고
    • Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes
    • Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 2000;23(Suppl 2):B54-B64.
    • (2000) Diabetes Care , vol.23 , Issue.2 SUPPL.
    • Estacio, R.O.1    Jeffers, B.W.2    Gifford, N.3    Schrier, R.W.4
  • 35
    • 0032513878 scopus 로고    scopus 로고
    • Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
    • HOT Study Group
    • Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755-1762.
    • (1998) Lancet , vol.351 , pp. 1755-1762
    • Hansson, L.1    Zanchetti, A.2    Carruthers, S.G.3    Dahlof, B.4    Elmfeldt, D.5    Julius, S.6    Menard, J.7    Rahn, K.H.8    Wedel, H.9    Westerling, S.10
  • 37
    • 0034627183 scopus 로고    scopus 로고
    • Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials
    • Blood Pressure Lowering Treatment Trialists' Collaboration
    • Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet. 2000;356:1955-1964.
    • (2000) Lancet , vol.356 , pp. 1955-1964
    • Neal, B.1    MacMahon, S.2    Chapman, N.3
  • 38
    • 0037341815 scopus 로고    scopus 로고
    • Outcomes with nifedipine GITS or co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT)
    • Mancia G, Brown M, Castaigne A, De LP, Palmer CR, Rosenthal T, Wagener G, Ruilope LM. Outcomes with nifedipine GITS or co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension. 2003;41:431-436.
    • (2003) Hypertension , vol.41 , pp. 431-436
    • Mancia, G.1    Brown, M.2    Castaigne, A.3    De, L.P.4    Palmer, C.R.5    Rosenthal, T.6    Wagener, G.7    Ruilope, L.M.8
  • 39
    • 0034729993 scopus 로고    scopus 로고
    • Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)
    • Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000;356:366-372.
    • (2000) Lancet , vol.356 , pp. 366-372
    • Brown, M.J.1    Palmer, C.R.2    Castaigne, A.3    De Leeuw, P.W.4    Mancia, G.5    Rosenthal, T.6    Ruilope, L.M.7
  • 41
    • 20444427156 scopus 로고    scopus 로고
    • Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: Principal results of a prospective randomized controlled study (MOSES)
    • Schrader J, Luders S, Kulschewski A, Hammersen F, Plate K, Berger J, Zidek W, Dominiak P, Diener HC. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke. 2005;36:1218-1226.
    • (2005) Stroke , vol.36 , pp. 1218-1226
    • Schrader, J.1    Luders, S.2    Kulschewski, A.3    Hammersen, F.4    Plate, K.5    Berger, J.6    Zidek, W.7    Dominiak, P.8    Diener, H.C.9
  • 42
    • 1642456664 scopus 로고    scopus 로고
    • Beta- and alpha-adrenergic cross-signaling for L-type Ca current is impaired in transgenic mice with constitutive activation of epsilonPKC
    • Yue Y, Qu Y, Boutjdir M. Beta- and alpha-adrenergic cross-signaling for L-type Ca current is impaired in transgenic mice with constitutive activation of epsilonPKC. Biochem Biophys Res Commun. 2004;314:749-754.
    • (2004) Biochem Biophys Res Commun , vol.314 , pp. 749-754
    • Yue, Y.1    Qu, Y.2    Boutjdir, M.3
  • 43
    • 0343674495 scopus 로고    scopus 로고
    • Changes in Ca(2+) cycling proteins underlie cardiac action potential prolongation in a pressure-overloaded guinea pig model with cardiac hypertrophy and failure
    • Ahmmed GU, Dong PH, Song G, Ball NA, Xu Y, Walsh RA, Chiamvimonvat N. Changes in Ca(2+) cycling proteins underlie cardiac action potential prolongation in a pressure-overloaded guinea pig model with cardiac hypertrophy and failure. Circ Res. 2000;86:558-570.
    • (2000) Circ Res , vol.86 , pp. 558-570
    • Ahmmed, G.U.1    Dong, P.H.2    Song, G.3    Ball, N.A.4    Xu, Y.5    Walsh, R.A.6    Chiamvimonvat, N.7
  • 44
    • 0036190137 scopus 로고    scopus 로고
    • Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes
    • Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002;61:1086-1097.
    • (2002) Kidney Int , vol.61 , pp. 1086-1097
    • Schrier, R.W.1    Estacio, R.O.2    Esler, A.3    Mehler, P.4
  • 46
    • 4644221457 scopus 로고    scopus 로고
    • Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
    • Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-1305.
    • (2004) N Engl J Med , vol.351 , pp. 1296-1305
    • Go, A.S.1    Chertow, G.M.2    Fan, D.3    McCulloch, C.E.4    Hsu, C.Y.5
  • 48
    • 84858539317 scopus 로고    scopus 로고
    • www.USRDS.org. Accessed June, 20 2005.
  • 49
    • 0035989568 scopus 로고    scopus 로고
    • Microalbuminuria: Marker of vascular dysfunction, risk factor for cardiovascular disease
    • Garg JP, Bakris GL. Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med. 2002;7:35-43.
    • (2002) Vasc Med , vol.7 , pp. 35-43
    • Garg, J.P.1    Bakris, G.L.2
  • 51
    • 20244382844 scopus 로고    scopus 로고
    • The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: Results of the African American Study of Kidney Disease and Hypertension
    • Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, Middleton J, Rostand SG, Miller E, Smith W, Bakris GL. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American Study of Kidney Disease and Hypertension. Arch Intern Med. 2005;165:947-953.
    • (2005) Arch Intern Med , vol.165 , pp. 947-953
    • Lea, J.1    Greene, T.2    Hebert, L.3    Lipkowitz, M.4    Massry, S.5    Middleton, J.6    Rostand, S.G.7    Miller, E.8    Smith, W.9    Bakris, G.L.10
  • 54
    • 3242668147 scopus 로고    scopus 로고
    • Clinical implications of blockade of the renin-angiotensin system in management of hypertension
    • Chua DY, Bakris GL. Clinical implications of blockade of the renin-angiotensin system in management of hypertension. Contrib Nephrol. 2004;143:105-116.
    • (2004) Contrib Nephrol , vol.143 , pp. 105-116
    • Chua, D.Y.1    Bakris, G.L.2
  • 55
    • 0031802190 scopus 로고    scopus 로고
    • Antihypertensive treatment of patients with proteinuric renal diseases: Risks or benefits of calcium channel blockers?
    • Kloke HJ, Branten AJ, Huysmans FT, Wetzels JF. Antihypertensive treatment of patients with proteinuric renal diseases: risks or benefits of calcium channel blockers? Kidney Int. 1998;53:1559-1573.
    • (1998) Kidney Int , vol.53 , pp. 1559-1573
    • Kloke, H.J.1    Branten, A.J.2    Huysmans, F.T.3    Wetzels, J.F.4
  • 56
    • 0029961207 scopus 로고    scopus 로고
    • Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy
    • Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int. 1996;50:1641-1650.
    • (1996) Kidney Int , vol.50 , pp. 1641-1650
    • Bakris, G.L.1    Copley, J.B.2    Vicknair, N.3    Sadler, R.4    Leurgans, S.5
  • 57
    • 0031657169 scopus 로고    scopus 로고
    • Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy
    • Bakris GL, Weir MR, DeQuattro V, McMahon FG. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int. 1998;54:1283-1289.
    • (1998) Kidney Int , vol.54 , pp. 1283-1289
    • Bakris, G.L.1    Weir, M.R.2    DeQuattro, V.3    McMahon, F.G.4
  • 58
    • 2442703942 scopus 로고    scopus 로고
    • Differential effects of calcium antagonist subclasses on markers of nephropathy progression
    • Bakris GL, Weir MR, Secic M, Campbell B, Weis-McNulty A. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int. 2004;65:1991-2002.
    • (2004) Kidney Int , vol.65 , pp. 1991-2002
    • Bakris, G.L.1    Weir, M.R.2    Secic, M.3    Campbell, B.4    Weis-McNulty, A.5
  • 59
    • 0031657216 scopus 로고    scopus 로고
    • Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy
    • Smith AC, Toto R, Bakris GL. Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int. 1998;54:889-896.
    • (1998) Kidney Int , vol.54 , pp. 889-896
    • Smith, A.C.1    Toto, R.2    Bakris, G.L.3
  • 60
    • 0032946830 scopus 로고    scopus 로고
    • Class differences in the effects of calcium channel blockers in the rat remnant kidney model
    • Griffin KA, Picken MM, Bakris GL, Bidani AK. Class differences in the effects of calcium channel blockers in the rat remnant kidney model. Kidney Int. 1999;55:1849-1860.
    • (1999) Kidney Int , vol.55 , pp. 1849-1860
    • Griffin, K.A.1    Picken, M.M.2    Bakris, G.L.3    Bidani, A.K.4
  • 62
    • 0035715175 scopus 로고    scopus 로고
    • Comparative effects of selective T- and L-type calcium channel blockers in the remnant kidney model
    • Griffin KA, Picken M, Bakris GL, Bidani AK. Comparative effects of selective T- and L-type calcium channel blockers in the remnant kidney model. Hypertension. 2001;37:1268-1272.
    • (2001) Hypertension , vol.37 , pp. 1268-1272
    • Griffin, K.A.1    Picken, M.2    Bakris, G.L.3    Bidani, A.K.4
  • 66
    • 3042819708 scopus 로고    scopus 로고
    • K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease
    • K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(5 Suppl 2):1-290.
    • (2004) Am J Kidney Dis , vol.43 , Issue.5 SUPPL. 2 , pp. 1-290


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.